Conquering Diseases

Extension of Investigational Drug for Participants of CENTAUR Study

Description

This is an extension of a study of the safety and effectiveness of an investigational drug to treat Amyotrophic Lateral Sclerosis (ALS)

Overview

This study is to give ALS patients who participated in the CENTAUR study longer-term access to the investigational drug AMX0035

What we're hoping for

We will evaluate the safety and effectiveness of the investgational drug AMX0035 for treatment of ALS

Additional Information

ClinicalTrials.gov Identifier: NCT03127514

 Principal Investigator

Margaret  Owegi, DO

UMass Memorial Health Care

 Study Contact

Catherine  Douthwright

508-856-6491

Catherine.Douthwright@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989